Breaking News

Tecnis Symfony IOL granted CE mark in Europe

Abbott has received CE mark in Europe for its Tecnis Symfony Extended Range of Vision IOL, indicated for cataract patients with presbyopia, according to a company press release.

“With the available advances in IOL technology, many patients are not satisfied with having to wear reading glasses after cataract surgery, which is often the result when using conventional monofocal IOLs,” Gerd U. Auffarth, MD, professor and chairman of the department of ophthalmology at Ruprecht-Karls University of Heidelberg, Germany, said in the press release. “The Tecnis Symfony Extended Range of Vision IOL enables physicians to offer patients a continuous range of functional vision for far, intermediate and near distances, with reduced risk of undesired halos or glare.”

Abbott has initiated a study in Europe to evaluate patients’ quality of vision at far, intermediate and near distances after the procedure is conducted in both eyes. The study will also examine surgeon and patient satisfaction, with preliminary data expected later this year.

Their post-marketing observational study data of 400 patients across Europe, including the United Kingdom, France, Germany and Spain, are also expected by the end of the year, according to the press release.

The lens is not yet approved for use in the United States.

Abbott has received CE mark in Europe for its Tecnis Symfony Extended Range of Vision IOL, indicated for cataract patients with presbyopia, according to a company press release.

“With the available advances in IOL technology, many patients are not satisfied with having to wear reading glasses after cataract surgery, which is often the result when using conventional monofocal IOLs,” Gerd U. Auffarth, MD, professor and chairman of the department of ophthalmology at Ruprecht-Karls University of Heidelberg, Germany, said in the press release. “The Tecnis Symfony Extended Range of Vision IOL enables physicians to offer patients a continuous range of functional vision for far, intermediate and near distances, with reduced risk of undesired halos or glare.”

Abbott has initiated a study in Europe to evaluate patients’ quality of vision at far, intermediate and near distances after the procedure is conducted in both eyes. The study will also examine surgeon and patient satisfaction, with preliminary data expected later this year.

Their post-marketing observational study data of 400 patients across Europe, including the United Kingdom, France, Germany and Spain, are also expected by the end of the year, according to the press release.

The lens is not yet approved for use in the United States.